WO1997036169A1 - In-vitro detection of reactions in blood to foreign substances - Google Patents
In-vitro detection of reactions in blood to foreign substances Download PDFInfo
- Publication number
- WO1997036169A1 WO1997036169A1 PCT/US1997/004849 US9704849W WO9736169A1 WO 1997036169 A1 WO1997036169 A1 WO 1997036169A1 US 9704849 W US9704849 W US 9704849W WO 9736169 A1 WO9736169 A1 WO 9736169A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- potential
- measured
- volume
- solids
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 108
- 239000008280 blood Substances 0.000 title claims abstract description 108
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 44
- 239000000126 substance Substances 0.000 title claims abstract description 44
- 238000000338 in vitro Methods 0.000 title claims description 7
- 238000001514 detection method Methods 0.000 title description 7
- 239000007787 solid Substances 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 40
- 238000005259 measurement Methods 0.000 claims description 26
- 239000011343 solid material Substances 0.000 claims 1
- 238000004364 calculation method Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 42
- 239000002245 particle Substances 0.000 description 38
- 239000007788 liquid Substances 0.000 description 36
- 239000000523 sample Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 15
- 239000000725 suspension Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000005672 electromagnetic field Effects 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000003068 static effect Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002934 lysing effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 238000011005 laboratory method Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000002977 intracellular fluid Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000002386 air freshener Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002560 nonimmunologic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- -1 thinners Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
- G01N33/48714—Physical analysis of biological material of liquid biological material by electrical means for determining substances foreign to the organism, e.g. drugs or heavy metals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/1031—Investigating individual particles by measuring electrical or magnetic effects
- G01N15/12—Investigating individual particles by measuring electrical or magnetic effects by observing changes in resistance or impedance across apertures when traversed by individual particles, e.g. by using the Coulter principle
Definitions
- the present invention is directed to the field of medical diagnoses, and, more specifically, diagnoses performed by detecting reactions in blood caused by the presence of foreign substances therein. I refer to this test as the "MRT" Test.
- the MRT Test relates to the field of hypersensitivity reactions observed in humans and animals. These reactions can be due to contact with offending substances such as medications, environmental chemicals, foods, carcinogens, food additives, etc.
- the MRT Test is an in- vitro assay which indirectly detects the release of mediators in whole blood after it is mixed with a test substance.
- a patient's blood reacts with the test substance, intracellular fluids are released, causing the liquid portion of blood to increase, while the total volume of the solids present in the blood decreases.
- These reactions may be caused by various immunologic and non-immunologic mechanisms.
- Blood is a liquid that circulates throughout the body using the vascular system and is in contact with practically every cell in the body. Blood delivers oxygen, food and other essential elements to all of our cells. Approximately 50% of blood is a fluid called serum (or plasma). It is a complex mixture of water, various proteins, carbohydrates, lipids, and electrolytes. Small amounts of other substances such as vitamins, minerals, and hormones are also found in blood. The other 50% of blood is comprised of solids such as erythrocytes (red blood cells: RBC), leukocytes (white blood cells: WBC), and thrombocytes (Platelets).
- RBC red blood cells
- WBC white blood cells
- thrombocytes Platinum
- the white blood cells are a significant part of our body's immune system.
- the immune system is highly complex and intricate in its design and is responsible for defending against foreign invaders such as bacteria, viruses, and other pathogens.
- the science of immunology incorporates the study of resistance to infections and the rejections of so called "foreign substances”.
- Types I-IV immune mediated hypersensitivity reactions and categorized them as Types I-IV, based upon the mechanics ofthe reaction. ' Types I. II, and III are identified as antibody mediated and the fourth one is described as cell mediated.
- Type I is the most widely occurring hypersensitivity reaction. It involves Mast cells and basophils, which bind IgE through their Fc receptors. After encountering the antigen, the antibody induces degranulation (the destruction ofthe exterior wall of the cell) and release of mediators.
- Type II reactions involve the binding of antigen and anv body on the surface of a cell, generally resulting in the destruction of the cell. As is the case in a Type I reaction, the final outcome of this reaction generates the release of cellular contents (including the release of the mediators).
- Type III reactions address the interactions of cells with complexes. Immune complexes, when deposited on tissue, cause complement activation, which in turn attracts polymo ⁇ honuclear leukocytes ("polymo ⁇ hs"). As their normal response, the polymo ⁇ hs will attempt phagocytosis on the complexes, but in many instances the complexes will be trapped by the tissue, blocking phagocytosis. As a natural course, polymo ⁇ hs will release inflammatory mediators.
- Type IV reactions involve sensitized T-lymphocytes. After the second contact with a specific antigen. T cells release lymphokines. which produces an inflammatory response, and in turn attracts mediator-releasing macrophages.
- reactions caused by immune, toxic, pharmacological and other mechanisms may cause d e release of mediators into the blood stream.
- a method of detecting reaction in blood caused by the presence of a foreign substance in the blood comprising the steps of: establishing a potential across a predetermined spatial volume; passing a first portion of the blood through the predetermined spatial volume; substantially continuously measuring the potential across the predetermined spatial volume over a first predetermined period of time; comparing the measured potential with a baseline; and calculating the total volume of solids in the first portion of the blood as a function of a total absolute deviation ofthe measured potential from the baseline.
- the same procedure is then followed with a second portion ofthe blood, after it has been exposed to the substance whose reaction is being determined.
- the two calculations are then compared, with a positive reaction being indicated when the two measured solid volumes are measurably different.
- an in-vitro method for detecting a reaction in blood caused by substances comprising the steps of: establishing a first potential across a first predetermined spatial volume: passing a first portion of the blood through the first predetermined spatial volume; substantially continuously measuring the first potential over a first predetermined period of time; comparing the measured first potential with a first baseline: calculating the total volume of solids in the first portion o the blood as a first function of a total absolute deviation of the measured first potential from said first baseline; exposing a second portion of the blood to a substance; establishing a second potential across a second predetermined spatial volume; passing the second portion of the blood through the second predetermined spatial volume; substantially continuously measuring the second potential over a second predetermined period of time; comparing the measured second potential with a second baseline; calculating the total volume of solids in the second portion of the blood as
- an in-vitro method for detecting a reaction in blood caused by substances comprising the steps of: establishing a first potential across a first predetermined spatial volume; passing a first portion ofthe blood through the first predetermined spatial volume; substantially continuously measuring the first potential over a first predetermined period of time; comparing the measured first potential with a first dynamic baseline; calculating the total volume of solids in the first portion of the blood as a first function of a total absolute deviation ofthe measured first potential from the first dynamic baseline; exposing a second portion of the blood to a substance; establishing a second potential across a second predetermined spatial volume; passing the second portion of the blood through the second predetermined spatial volume; substantially continuously measuring the second potential over a second predetermined period of time; comparing the measured second potential wid a second dynamic baseline; calculating the total volume of solids in the second portion of the blood as a second function of a total absolute deviation of the measured second potential from the second dynamic baseline; and comparing the total volume of solids in the
- Figure 1 illustrates an idealized particle (balloon) having a volume of 300 ⁇ l, in a unit volume of 1 ml of a suspension, leaving a liquid volume of 700 ⁇ l.
- Figure 2 illustrates an identical unit volume of 1 ml (not drawn to scale), in which the particle has a volume of only 100 ⁇ l, and the liquid a resultant volume of 900 ⁇ l.
- Figure 3 illustrates an actual oscilloscope reading of a series of particles being measured as they pass through the electromagnetic field under observation.
- Figure 4 shows a close up of some oscilloscope readings such as depicted in Fig. 3.
- Figure 5 shows a smoothed curve showing three particles passing through the electromagnetic field being measured.
- Figure 6 shows an idealized representation of a series of particles passing through the electromagnetic field.
- Figure 7 shows an idealized representation of a comparison of test and control sample readings as the particles pass through the electromagnetic field.
- the MRT Test relies in large part upon the performance of the test described in my co ⁇ pending PCT application, and reference is made thereto for a more complete understanding of the mechanics ofthe testing being done. The following is presented for convenience of reference.
- supplies and Instrumentation may vary to some extent and depend on the type of testing instrument employed for the MRT Test. In this case I have chosen the semi-automated STSIOO manufactured by Signet Diagnostic Co ⁇ oration. and the following description is made with that device as a reference).
- adjustable multi pipette 10-20 ml dispenser e.g. an Oxford pipetor to dispense the electrolytic solution mixed with a lysing agent body temperature incubator, e.g. by Precision Scientific 60-100 ⁇ m rotator, e.g. by Roto Mix 70 ml blood dilution vial with diluent lysing reagent (as described in my prior patents) 8 ml vial testing cuvettes with reagents.
- the reagents are dried and diluted food extracts, e.g. by ALK or Bayer.
- isotonic (electrolytic) solution e.g. Osmocel Isotonic Solution by Hematronic Apparatus, STSIOO or STS200 made by Signet Diagnostic Co ⁇ .
- Control samples contain no reagent.
- Test samples contain a small amount of a substance being evaluated, the "reagent”.
- the control sample serves as a finge ⁇ rint ofthe patient's blood.
- the test sample provides information related to the reaction ofthe tested substance to the reagent being tested. IV. After transferring blood to all tested samples, mix all cuvettes and cap them.
- VIL Remove from incubator and follow by 30 minutes room temperature incubation. Total of 60 minutes incubation. 3. Testing:
- the MRT Test the new proprietary laboratory method, can be described in the following fashion:
- step "c" Measure total volume of liquid and or solids in native blood sample by means ofthe method described in my prior PCT application.
- step "d" Measure total volume of liquid and/or solids in the mixture of blood and tested substance sample. If in step "c", you measure liquids, then do so here. Likewise with solids, so that comparisons may be made "like-to-like”.
- step "d" for each tested substance. This may be done in parallel, i.e. several test measurements taken at the same time, or one after another.
- f Identify volumetric differences of liquid volume and or solid volume between native blood sample and the tested blood sample. g. Prepare the results identifying the measured volumetric differences. h. Identify the positive and negative reactions, by noting which reagents produced a measurable reaction, i.e. one greater than the standard deviation expected for the test, calculated in known fashion.
- Figure 1 represents a small cuvette containing 1 ml of heterogeneous fluid.
- the liquid portion is equivalent to 700 ⁇ l.
- the balloon filled with black ink has an equivalent volume of 300 ⁇ l. Note that for pu ⁇ oses of measurement the balloon would be considered as a solid entity.
- This example illustrates how human blood cells react in the body.
- the reacting substance When the reacting substance is introduced to the blood, it triggers a series of complex reactions.
- the intracellular fluids will be released into the plasma, changing the original ratio of solids to liquid.
- the ratio is the key for identifying the malady (the intracellular liquids contain the mediators causing the clinical symptomology), but the ratio can be determined easily from a measurement of either the solid or the liquid volume per unit volume ofthe blood suspension.
- the basic apparatus is shown in my prior PCT patent application, and includes an aperture tube in which the blood suspension is drawn into an orifice and along an aperture.
- An electromagnetic field is imposed upon the aperture, and the blood suspension is drawn through the field. Since the liquid of the suspension is essentially homogeneous, and conductive, while the blood cells are resistive, with their resistivity varying with their size, the size of the blood cells passing through the aperture may be calculated by measuring the perturbation of the field as the particles pass therethrough.
- the new method does not adhere to the standard peak detection. It continuously measures the flow of volume of liquid and solids in the tested liquid.
- the series of spikes represent particles causing small disturbances in the electrical field.
- the longer and higher the pulse the greater the volume ofthe particle (See printout identified as Figure 4). Accordingly, a smaller particle will create a shorter disturbance of a smaller magnitude, and a larger particle will cause a longer disturbance of a greater magnitude.
- Figure 5 explains how the MRT measurement works and how it differs from the Coulter Method.
- a disturbance caused by particle "PI” produces the spike with the peak high's marked “h,”. It is measured from the base level up to the peak of the signal. After the particle travels the length ofthe aperture, the measured signal experiences a "bounce” in which the measured signal goes below the original baseline, and gradually goes on an upward gradient towards the original baseline. But a subsequent particle may often enter the aperture before the "bounce” is over.
- second particle “P2” starts its disturbance below the static base level. The height of h 2 is measured from the baseline and clearly shows, that the result is not very accurate since the true disturbance commences below that level.
- the third particle (P3) is a platelet and its electrical disturbance is entirely below the base level, due to the large "bounce” caused by P2, and so is invisible to the instrument.
- the lower size limit of particles which may be measured is determined by the static noise threshold established during calibration.
- the upper size limit is related to the physical size of the aperture.
- a major problem associated with electric resistance particle counting and sizing becomes evident when attempts are made to evaluate two dissimilar particle sizes at the same time using the same aperture, e.g. simultaneous measurement of erythrocytes and platelets. After cells pass through the orifice, some re-enter the electrical field with the pulse resembling the size of platelets. Threshold and electrical "noises” are also a substantial problem.
- a specific constant threshold is set during the calibration which controls the minimum level of signal detection. This in turn lowers the presence ofthe electronic "noise". When the voltage change exceeds the level ofthe threshold, the instrument will identify the peak of that impulse. This is the basis ofthe peak detection method.
- the time is measured as the duration of the interval commencing when the gradient ofthe curve begins to indicate the presence ofa particle until the measured signal returns to its original level.
- the presence of the particle is indicated when the gradient increases for a predetermined period, preferably corresponding to at least three consecutive measurement clock cycles.
- V L2 time identified as "V L2 ". This is the time it takes fluid to pass through the orifice.
- V S2 the point “V S2”
- another particle "P2” enters the orifice.
- the signal is still below the static threshold and the static baseline, but the STSIOO instrument recognizes the condition and begins to measure the solid particle.
- H The height ofthe perturbation of the signal is therefore measured as H , from the dynamic baseline, rather than from the static baseline as shown by h 2 . This more accurately reflects the true size ofthe perturbation ofthe signal, and therefore the size ofthe particle.
- the duration ofthe signal identified as "V L2 " is another important part ofthe measurement. If we look at signal "P3". it is evident, that the whole impulse is contained below the baseline. The volume ofthe solid, identified by time “V 3 " arid measured from the dynamic baseline becomes part ofthe measurement.
- the MRT Ribbon Method thus correctly measures all particles suspended in the electrolytic solution. There is a definite relationship between the length, height and volume of the tested particle. Since the STS200 apparatus measures with a frequency greater then 1 MHZ, it is easy to identify the relationship between the size ofthe particle and the time it will need to pass through the orifice. Also the flow of fluid is identified.
- the gradient of the curve on the upward slope of the curve when a particle is present also varies with the size of the particle, larger particles having a steeper slope.
- the exact relationship depends upon the configuration of the system, and may be determined with some minor experimentation depending upon the parameters ofthe equipment being used. Thus, the gradient may also be used to calculate the size of the particles.
- Figure 6 graphically represents how the STS200 identifies the volume of solid and the volume of liquid.
- V L Volume in time in which an instrument measures the liquid
- V s Volume in time in which an instrument measure the solid particle.
- V ⁇ V LT + V s ⁇
- the fluid flows through the orifice.
- the liquid portion is characterized by the flat impulse line and the solid portion is characterized as the visual disturbance in the flat impulse signal.
- the computer software program quantifies the cumulative volume of liquid and cumulative volume of solids in accordance with the rules established, here. There are at least three different ways of data collection and results presentation:
- the next step repeats the preparation process ofthe sample cuvette.
- Results will be calculated from the information obtained from all samples, by comparing the total volume of liquid of control sample to the total volume of liquid ofthe substance sample. We will obtain two results from each substance. One sample will give us information on the activities ofthe Red Blood Cells (RBC) and another sample will inform us . pn reactions of all other then RBC blood components in presence of tested substance. It is not mandatory to conduct the MRT Test in this exact fashion. Per individual need, one can conduct the partial test obtaining results from the first or the second solution only. 4.
- the computer will establish the volumetric baseline of the plasma (liquid) present in one cubic millimeter of control blood sample. Once the baseline is established, the actual volume of plasma present in each milliliter of each blood sample will be calculated and compared against the actual volume of plasma in the control sample. If liquid volume in the control sample significantly varies from liquid volume in the test sample, the tested substance is identified as reacted. A significant reaction would be one greater than could be attributed to the known instrumentation error plus the standard deviation for similar measurements. Any difference of less than that amount would not necessarily indicate a positive reaction, since it could be attributed to statistical or instrumentation error.
- Figure 7 portrays the measurement ofthe blood sample distribution ofthe Control and Test Samples. The differences between the distribution patterns would be due to the exposure ofthe Test Sample to the tested substance.
- the computer program will calculate the variation and save it as the results data. Inte ⁇ retation of results will be based on the standard deviations and other generally accepted laboratory methods of results inte ⁇ retation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002250125A CA2250125C (en) | 1996-03-25 | 1997-03-25 | In-vitro detection of reactions in blood to foreign substances |
EP97917620A EP0998669A4 (en) | 1996-03-25 | 1997-03-25 | In-vitro detection of reactions in blood to foreign substances |
US09/155,364 US6114174A (en) | 1995-08-01 | 1997-03-25 | In-vitro detection of reactions in blood to foreign substances |
AU25895/97A AU2589597A (en) | 1996-03-25 | 1997-03-25 | In-vitro detection of reactions in blood to foreign substances |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1406096P | 1996-03-25 | 1996-03-25 | |
US60/014,060 | 1996-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997036169A1 true WO1997036169A1 (en) | 1997-10-02 |
Family
ID=21763317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/004849 WO1997036169A1 (en) | 1995-08-01 | 1997-03-25 | In-vitro detection of reactions in blood to foreign substances |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0998669A4 (en) |
AU (1) | AU2589597A (en) |
WO (1) | WO1997036169A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4021117A (en) * | 1975-08-07 | 1977-05-03 | Hildegard Gohde | Process for automatic counting and measurement of particles |
US4788155A (en) * | 1983-11-01 | 1988-11-29 | Pasula Mark J | Method and apparatus for measuring the degree of reaction between a foreign entity and a subject's blood cells |
US5376878A (en) * | 1991-12-12 | 1994-12-27 | Fisher; Timothy C. | Multiple-aperture particle counting sizing and deformability-measuring apparatus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3733548A (en) * | 1971-04-28 | 1973-05-15 | Coulter Electronics | Apparatus and method for measuring particle concentration of a suspension passing through a sensing zone |
EP0549599A1 (en) * | 1990-07-17 | 1993-07-07 | Mark J. Pasula | Blood testing apparatus |
-
1997
- 1997-03-25 EP EP97917620A patent/EP0998669A4/en not_active Withdrawn
- 1997-03-25 AU AU25895/97A patent/AU2589597A/en not_active Abandoned
- 1997-03-25 WO PCT/US1997/004849 patent/WO1997036169A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4021117A (en) * | 1975-08-07 | 1977-05-03 | Hildegard Gohde | Process for automatic counting and measurement of particles |
US4788155A (en) * | 1983-11-01 | 1988-11-29 | Pasula Mark J | Method and apparatus for measuring the degree of reaction between a foreign entity and a subject's blood cells |
US5376878A (en) * | 1991-12-12 | 1994-12-27 | Fisher; Timothy C. | Multiple-aperture particle counting sizing and deformability-measuring apparatus |
Non-Patent Citations (1)
Title |
---|
See also references of EP0998669A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP0998669A4 (en) | 2004-11-17 |
EP0998669A1 (en) | 2000-05-10 |
AU2589597A (en) | 1997-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120028845A1 (en) | Sensor for Detecting Biological Agents in Fluid | |
US4191739A (en) | Antigen-antibody reaction assay employing particle aggregation and resistive pulse analysis | |
WO1997026528A1 (en) | Method and apparatus for determination of hemoglobin content of individual red blood cells | |
CN1091521A (en) | Target component assay | |
Barni et al. | Detection of allergen-IgE interaction in allergic children through combined impedance and ROS measurements | |
Brittin et al. | Automated optical counting of blood platelets | |
CN112698024B (en) | Immunoassay method based on differential impedance particle counting | |
EP0870187B1 (en) | Method for testing a cell sample | |
CA1311404C (en) | Automated analyzer and method for screening cells or formed bodies for enumeration of populations expressing selected characteristics | |
US6114174A (en) | In-vitro detection of reactions in blood to foreign substances | |
Chiron et al. | The GEN. S: a fortuitous finding of a routine screening test for hereditary spherocytosis | |
CN111033256A (en) | Alarming method of platelet aggregation sample, blood cell analyzer and storage medium | |
CA2250125C (en) | In-vitro detection of reactions in blood to foreign substances | |
EP0998669A1 (en) | In-vitro detection of reactions in blood to foreign substances | |
EP1058830B1 (en) | A method of analysing a sample of free cells | |
Ćwiklińska et al. | The results of external quality assessment programme on urine leukocyte and erythrocyte counting in Poland | |
US5907240A (en) | Method and apparatus for cell differentiation by measuring apparent cell size, membrane integrity and intracellular complexity | |
JPH08500437A (en) | Method for determining an allergenic response to an antigen in a mammalian blood specimen | |
EP3025781B1 (en) | A method for determinig agglutination | |
WO2009018210A1 (en) | Method for measuring multiple analytes using flow cytometry | |
Haynes | High-Resolution Particle Analysis—Its Application to Platelet Counting and Suggestions for Further Application in Blood Cell Analysis | |
Lewis | New developments in haematology | |
Lombarts | Studies on quality assurance in haemocytometry | |
Cook et al. | Laboratory Instrumentation, Reagents, Methods, and Patient Sample as Variables in Coagulation | |
CN116601495A (en) | Methods for assessing metabolic activity of non-tumor cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2250125 Country of ref document: CA Ref country code: CA Ref document number: 2250125 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09155364 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997917620 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97534576 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997917620 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997917620 Country of ref document: EP |